Cardiovascular Diseases

Aspirin for Primary Prevention Challenged

Findings of two randomized, placebo controlled clinical trials challenged the role of aspirin in primary prevention in a low-risk population and in patients of diabetes. A randomized, double-blind, placebo-controlled, multicenter study was done in seven countries. Between July 5, 2007, and Nov 15, 2016, 12 546 eligible patients aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk were randomly assigned to receive enteric-coated aspirin (100 mg daily, n=6270) or placebo (n=6276). During median follow-up of 60 months, in the intention-to-treat analysis, the primary endpoint (a composite outcome of time to first occurrence of cardiovascular death, myocardial infarction [MI], unstable angina, stroke, or transient ischemic attack [TIA]) occurred in 269 (4.29%) patients in the aspirin group versus 281 (4.48%) patients in the placebo group (hazard ratio [HR] 0.96). Gastrointestinal bleeding events (mostly mild) occurred in 61 (0.97%) patients in the aspirin group versus 29 (0.46%) in the placebo group (HR 2.11). Documented deaths and the overall incidence rate of adverse events was similar in both groups. Another total of 15,480 participants with diabetes but no evident cardiovascular disease (CVD) were randomized to receive aspirin at a dose of 100 mg daily or matching placebo in the UK. During a mean follow-up of 7.4 years, serious vascular events (i.e., MI, stroke or TIA, or death from any vascular cause, excluding any confirmed intracranial hemorrhage) occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; HR 0.88). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (HR 1.29), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin and the placebo groups in the incidence of gastrointestinal tract cancer or all cancers. The benefits of aspirin for patients with CVD are well established but not in primary prevention. Source: https://www.thelancet.com/; https://www.nejm.org/

hyangiu

Recent Posts

Dose Response of Physical Activity in CVD and Mortality

Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular…

1 day ago

Faster Walking Pace May Reduce Risk of Cardiac Arrhythmias

A prospective UK cohort study found that both self-reported average or brisk walking pace and…

2 days ago

4:3 Intermittent Fasting Outperforms Daily Caloric Restriction for Weight Loss

A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater…

4 weeks ago

Comparative CVD Efficacy of Newer Glucose-Lowering Drugs in Elderly T2D Patients

A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor…

1 month ago

Efficacy of Non-Surgical and Non-Interventional Treatments in Low Back Pain

A systematic review and meta-analysis of placebo-controlled randomized trials showed that there is moderate certainty…

1 month ago

Statin Use Linked to Lower Risks of HCC and Liver Disease Progression

A US cohort study indicated that statin use may reduce the risks of hepatocellular carcinoma…

1 month ago

This website uses cookies.